AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of the claims in the application.

1. **(Previously Presented)** A method of inhibiting activation of a lymphocyte in a patient that may benefit from inhibition of lymphocyte activation, the method comprising administering to the patient a soluble form of B7-H3 and allowing the soluble form of B7-H3 to inhibit the activation of the lymphocyte.

2. (Canceled)

3. (Withdrawn) The method as in claim 3, wherein the B7-H3 agonist comprises SEQ ID NO:15.

4. **(Previously Presented)** The method as in claim 1, wherein the soluble form comprises at least one V domain of B7-H3.

5. **(Previously Presented)** The method as in claim 4, wherein the V domain comprises: (a) SEQ ID NO:7 or (b) an amino acid sequence which is at least 90% identical to SEQ ID NO:7 and wherein the soluble form exhibits a biological activity selected from the group consisting of decreasing T cell proliferation, decreasing secretion of IL-10, decreasing secretion of IFN-γ, decreasing secretion of GMCSF, and decreasing secretion of TNF-α.

6. **(Original)** The method as in claim 4, wherein the soluble form of B7-H3 further comprises at least one C domain of B7-H3.

7. **(Original)** The method as in claim 4, wherein the soluble form of B7-H3 further comprises an Fc region of an antibody.

8. **(Currently Amended)** The method as in claim 7, wherein the soluble form of B7-H3 comprises: (a) an amino acid sequence chosen from SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22; or (b) an amino acid sequence which is at least 90% identical to ~~at least one of the sequences chosen from SEQ ID NO:16, SEQ ID NO:17,~~ SEQ ID NO:18~~, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22~~ and wherein the soluble form exhibits a biological activity selected from the group consisting of decreasing T cell proliferation, decreasing secretion of IL-10, decreasing secretion of IFN-γ, decreasing secretion of GMCSF, and decreasing secretion of TNF-α.

9. **(Previously Presented)** The method as in claim 7, wherein the soluble from of B7-H3 comprises: (a) an amino acid sequence chosen from SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; or (b) an amino acid sequence which is at least 90% identical to at least one of the sequences chosen from SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14 and wherein the soluble form exhibits a biological activity selected from the group consisting of decreasing T cell proliferation, decreasing secretion of IL-10, decreasing secretion of IFN-γ, decreasing secretion of GMCSF, and decreasing secretion of TNF-α.

10. (Withdrawn) The method as in claim 3, wherein the B7-H3 agonist is coupled with a primary stimulatory molecule.

11. (Withdrawn) The method as in claim 10, wherein the soluble form of B7-H3 and the primary stimulatory molecule are spaced by no more than 100 μm.

12. (Withdrawn) The method as in claim 1, wherein the B7-H3 antagonist is a nucleic acid encoding amino acid of SEQ ID NO:15.

13. (Withdrawn) A method of enhancing activation of a lymphocyte, the method comprising contacting the lymphocyte with a B7-H3 antagonist and allowing the antagonist to enhance the activation of the lymphocyte.

14. (Withdrawn) The method as in claim 13, wherein the lymphocyte is human.

15. (Withdrawn) The method as in claim 13, wherein the B7-H3 antagonist is an antibody to B7-H3 or an antibody against a B7-H3 receptor.

16. (Withdrawn) The method as in claim 13, wherein the B7-H3 antagonist is an antisense nucleic acid or a siRNA.

17. **(Previously Presented)** The method as in claim 1, wherein the lymphocyte is a T cell.

18. **(Previously Presented)** The method as in claim 17, wherein the T cell is a $CD4^+$ T cell.

19. (Canceled)

20. **(Previously Presented)** The method as in claim 1, wherein the patient is afflicted with an immunologic disorder selected from the group consisting of rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis, type I diabetes, transplant rejection, and graft-versus-host disease.

21. **(Currently Amended)** The method as in claim 1 [[9]], wherein the patient is treated with Factor VIII or Factor IX.

22. **(Previously Presented)** The method as in claim 1, wherein the patient is at risk for transplant rejection or graft-versus-host disease.